Beryl Drugs (BOM:524606) Cash-to-Debt : 0.13 (As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Beryl Drugs's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.13.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Beryl Drugs couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Beryl Drugs's Cash-to-Debt or its related term are showing as below:

BOM:524606' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.13 Max: 0.49
Current: 0.24

During the past 13 years, Beryl Drugs's highest Cash to Debt Ratio was 0.49. The lowest was 0.03. And the median was 0.13.

BOM:524606's Cash-to-Debt is ranked worse than
73.4% of 1045 companies
in the Drug Manufacturers industry
Industry Median: 0.92 vs BOM:524606: 0.24

Beryl Drugs Cash-to-Debt Historical Data

The historical data trend for Beryl Drugs's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Beryl Drugs Cash-to-Debt Chart

Beryl Drugs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

0.08

0.13

Beryl Drugs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.13	N/A	0.24	N/A	0.13

Competitive Comparison of Beryl Drugs's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beryl Drugs's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's Cash-to-Debt falls into.

Beryl Drugs Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Beryl Drugs's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.613	/	(26.901	+	24.038)
	=	0.13

Beryl Drugs's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.613	/	(26.901	+	24.038)
	=	0.13

Beryl Drugs (BOM:524606) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Beryl Drugs Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Beryl Drugs (BOM:524606) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001

Website

http://www.beryldrugs.com

Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs (BOM:524606) Headlines

No Headlines